Based on of these preclinical studies, in 2018, started an open label trial to test the effects of oral EGCG treatment on lung tissues and serum samples obtained from 20 patients with IPF and it is titled “Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.” Half of the patients were given orally EGCG before they underwent biopsy, and the other half did not receive the treatment. Here, TGFB1 is linked to pulmonary fibrosis.